Request Demo

Last update 23 Jan 2025

fetal inflammatory response syndrome

Last update 23 Jan 2025

Basic Info

Synonyms

FIRS fetal inflammatory response syndrome, LPS-induced FIRS, LPS-induced fetal inflammatory response syndrome

+ [7]

Introduction-

Drugs associated with fetal inflammatory response syndrome

Resatorvid

Target

TLR4

Mechanism

TLR4 antagonists

Active Org.-

Originator Org.

Takeda Pharmaceutical Co., Ltd.

Active Indication-

Inactive Indication

Acute-On-Chronic Liver Failure [+8]

Drug Highest PhaseDiscontinued

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

BI-653048

Target

Mechanism

GR agonists

Active Org.-

Originator Org.

Boehringer Ingelheim GmbH

Active Indication-

Inactive Indication

fetal inflammatory response syndrome

Drug Highest PhasePending

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with fetal inflammatory response syndrome

NCT05717933

/ Not yet recruitingNot ApplicableIIT

Thyroid Function Among Pediatric Patients With Type 1 Diabetes Mellitus at Firs Presentation, From Patients' Characteristics to Disease Severity

Thyroid function among pediatric patients with type1 diabetes mellitus at the first presentation, from patients' characteristics to disease severity

Start Date01 Feb 2023

Sponsor / Collaborator

Assiut University

ChiCTR2100052175

/ SuspendedNot ApplicableIIT

Association Between Fetal Inflammatory Response Syndrome and Bronchopulmonary Dysplasia in Premature Infants: A Case-Control Study

Start Date20 Oct 2021

Sponsor / Collaborator-

NCT02702297

/ CompletedNot Applicable

Multimodales Monitoring Des Fetalen Inflammationsrisikos Bei frühem Vorzeitigen Blasensprung (PPROM)

The purpose of this study is to examine whether the value of vaginal fluid cytokine levels as well as computerized fetal ECG analysis are suitable clinical parameters to detect an imminent intra-amniotic inflammation with a high risk of fetal inflammatory response syndrome (FIRS) or a neonatal early onset sepsis (EOS) and whether these parameters can be determined on a daily basis in the clinical monitoring of pregnancies complicated by PPROM.

Start Date07 Jan 2016

Sponsor / Collaborator

Martin-Luther-Universität Halle-Wittenberg

[+2]

100 Clinical Results associated with fetal inflammatory response syndrome

100 Translational Medicine associated with fetal inflammatory response syndrome

0 Patents (Medical) associated with fetal inflammatory response syndrome

1,420

Literatures (Medical) associated with fetal inflammatory response syndrome

01 Dec 2025·Current Cardiology Reports

Sepsis-Associated Cardiomyopathy: Long-Term Prognosis, Management, and Guideline-Directed Medical Therapy

Review

Author: Hollenberg, Steven M

PURPOSE OF REVIEWTo explore the definitions of sepsis-induced cardiomyopathy and how that impacts interpretation of the available data and considerations of long-term prognosis and management.RECENT FINDINGSThe field of sepsis-induced cardiomyopathy has been hampered by lack of consensus about its proper definition, with a great deal of heterogeneity in clinical trial data in both individual studies and meta-analyses and consequent disparity of estimates of incidence, prognosis, and clinical significance. New diagnostic techniques, while potentially shedding light on pathophysiology, have only exacerbated these challenges. There are few persuasive data to suggest that decreased ejection fraction consequent to sepsis-induced cardiomyopathy merits a treatment strategy different from other causes, except that improvement may be more likely inasmuch as the classic description includes reversibility over 7 to 10 days. For persistent cardiac dysfunction after sepsis, whether pre-existing or newly diagnosed, institution and titration of guideline-directed medical therapy for HFrEF seems to be the most logical strategy. Armed with a clear understanding of what parameters of cardiac function are most important, clinicians can develop therapeutic strategies that make sense and calibrate them according to the clinical response.

01 Apr 2025·Domestic Animal Endocrinology

17β-estradiol inhibits lipopolysaccharide-induced inflammation and pyroptosis of Leydig cells of the domestic yak (Bos grunniens) via the SIRT1/Nox4/ROS pathway

Article

Author: Wang, Jin'e ; Chen, Zhou ; Yang, Yahua ; Ma, Junyuan ; He, Wen ; Huo, Shengdong ; Yang, Yanmei ; Niu, Xiaoying ; Hu, Songming ; Li, Yang ; He, Lin ; Zhaxi, Yingpai ; Yang, Chongfa

Estradiol (E2) secreted by Leydig cells (LCs) can accumulate in the testes due to constriction of the reproductive lumen. Estrogen is not only important for reproduction, but also protects against inflammation. In this study, the role of pyroptosis in testicular inflammation and the effects of E2 against inflammation and pyroptosis of yak interstitial cells were investigated. Inflamed testes exhibited structural damage and pyroptosis with decreased E2, testosterone, and estrogen receptor β (ERβ) levels in testicular fluid. E2 alone inhibited testosterone secretion and increased ERβ expression in mature LCs. In LCs, lipopolysaccharide (LPS) causes inflammation by activation of TNF-α and IL-6, and pyroptosis via activation of the classical and non-classical pyroptosis pathways. LPS inhibits sex hormone secretion and ERβ expression in LCs. E2 inhibited the LPS-induced decrease of ER expression in LCs and also inhibited LPS-induced interstitial cell inflammation and pyroptosis, which was partially blocked by Selisistat (EX-527, SIRT1 inhibitor) or Fulvestrant (ICI 182,780, E2 non-genomic receptor inhibitors). In conclusion, E2 relieved LPS-induced inflammation and pyroptosis of yak LCs via the SIRT1/Nox4/ROS pathway. This finding provides new insights into the role of estrogen in male reproductive health and offers a potential therapeutic strategy to improve testicular immune and reproductive function by modulating hormonal homeostasis.

01 Feb 2025·Poultry Science

Alleviating effects of dietary formic acid polymer supplementation on lipopolysaccharide-induced inflammatory injury in gut-liver axis of broilers

Article

Author: Jiang, Shuzhen ; Zhou, Guohui ; Yang, Weiren ; Li, Yang ; Yuan, Xuejun ; Fu, Yuemeng ; Jiao, Ning ; Chen, Jiali

A close interplay exists between the gut and liver, known as the "gut-liver axis", which plays a vital role in health and disease. This research aimed to explore the effects of dietary formic acid polymer (FAP) addition on inflammatory injury in gut-liver axis of broilers due to lipopolysaccharide (LPS) challenge. Four hundred and fifty 1-day-old male Arbor Acres broilers were assigned to three treatment groups: (1) control (non-challenged, basal diet); (2) LPS (LPS-challenged, basal diet); (3) LPS+FAP (LPS-challenged, basal diet with 1,000 mg/kg FAP). The trial lasted 21 days. On experimental days 17, 19, and 21, the LPS and LPS+FAP groups were intraperitoneally administered LPS (1 mg/kg BW), and the control group received an equal volume of physiological saline via intraperitoneal injection. Results showed that LPS injection induced inflammatory response, resulted in liver damage, and destroyed intestinal morphology and mucosal barrier. However, dietary FAP supplementation alleviated LPS-induced adverse effects on liver and small intestine by decreasing inflammatory response and suppressing cell death. In conclusion, supplementation of 1000 mg/kg FAP mitigated LPS-induced inflammatory injury in gut-liver axis in broilers.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

fetal inflammatory response syndrome

Basic Info

Related

Analysis